The company plans to launch two new studies aimed at evaluating the experimental treatment across a wider patient population. This strategic shift follows promising Phase 2 data, which indicated that over half of the participants experienced measurable tumor shrinkage, with the therapeutic response proving durable over time.

Chief Executive David Hung described the move as a pivotal progression for the drug, shifting the focus toward capturing a more diverse landscape of glioma cases. While the recent market surge offers a reprieve for investors, the company remains focused on translating these clinical milestones into long-term medical viability for patients battling IDH1-mutant tumors.